SEC Form 4 · accession 0002079859-26-000002
Decoy Therapeutics Inc. · DCOY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Klaus Marschel
Officer — Chief Business Officer
Period of report
Aug 31, 2026
Accepted (ET)
Sep 2, 2026 · 5:49 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001615219
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 31, 2026 | A | 3,900 | $0.00 | A | 3,900 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.